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INTRODUCTION
 Diabetes Mellitus is a serious public health 
concern with a worldwide estimated prevalence 
of 460 million in the adult population of age 
between 20 to 79 years and 79.4% of this estimation 
is living in low to middle-income countries 
including Pakistan.1 In Pakistan estimated 
prevalence of diabetes mellitus is about 17.1%1 
with compliance of only 60 % with prescribed 
anti diabetic medications.2 Diabetes mellitus 
Type-2 (T2DM) is a slowly progressive metabolic 
disorder characterized by insulin resistance and a 
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ABSTRACT
Objective: To determine the efficacy and safety of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use 
in the Pakistani population.
Methods: Retrospective review of initial 100 patients who were prescribed with any agent of the SGLT2i 
group from July 1, 2018 to January 2019 at Aga Khan University Hospital, Karachi. SGLT2i was offered 
to patients of above 18 years of age with inadequate glycemic control on existing antidiabetic agents. 
Changes in HbA1c, the Body Mass Index (BMI), serum creatinine, any decrease in the requirement of insulin 
and sulphonylurea dose along with any side effects reported by the patients on follow-up visits. 
Results: Most study participants were females (56%) with the mean age of 52±10 years. Substantial changes 
were observed in the HbA1c (7.5±1.1%, 7.9±1.2% from 8.7±1.5%, p < 0.01), BMI (31.4±5.8, 31.8±5.8 from 
32.4±5.9kg/m2, p < 0.01) and in creatinine (0.71±0.1, 0.75±0.1 from 0.79±0.1 mg/dl, p < 0.01) at three 
and six months of follow up visits. The reduction in insulin and sulphonylurea doses was also significant. 
Adverse drug events that led to drug discontinuation in 14 individuals were, Urinary tract infection (UTI) 
(seven patients), Genital infection (three patients), nausea +UTI, abdominal pain +UTI, mild Diabetic 
Ketoacidosis, and polyuria (one patient each). None reported Fournier’s gangrene, limb amputation, or 
fracture.
Conclusion: SGLT2i significantly improved glycemic control, BMI, and serum creatinine in the Pakistani 
population with a very low number of observed adverse events.
KEYWORDS: Glycated Hemoglobin A, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, 
Diabetes Mellitus, Type-2.
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progressive defect in insulin secretion associated 
with severe macrovascular and microvascular 
complications.3 Because of its progressive nature, 
it needs multiple anti-diabetic agents for achieving 
and maintaining optimum glycemic control, 
unfortunately, more than 50 to 70% of patients 
with T2DM failed to achieve and maintain their 
glycemic control at some stage.4,5 Sodium-glucose 
co-transporter 2 inhibitors (SGLT2i) are the new 
oral agents for the management of T2DM that can 
be used as an add on therapy with other oral agents 
and insulin or as a monotherapy at any stage of 
diabetes. These novel agents improve glycemic 
control by inhibiting glucose reabsorption through 
SGLT2 transmembrane proteins at the level of 
proximal renal tubules and re-entering circulation.6 
Selective inhibition of SGLT2 has shown a potent 
antihyperglycemic effect with additional favorable 
effects such as reduction in the weight and blood 
pressure.7
 Since the results of large trials on this group, 
empagliflozin cardiovascular outcome event trial 
(EMPA-REG OUTCOME), dapagliflozin effect on 
cardiovascular events–thrombolysis in myocardial 
infarction 58 (DECLARE-TIMI58) and canagliflo-
zin cardiovascular assessment study (CANVAS), 
it has been shown that these newer oral anti-dia-
betic agents reduce the incidence of cardiovascular 
events in patients with T2DM and established car-
diovascular disease,8-10 there has been great interest 
of endocrinologists and cardiologists in expanding 
use of this group of drug in  T2DM patients with 
cardiovascular diseases, especially heart failure.11
 Empagliflozin and dapagliflozin are the two 
FDA approved drugs of this SGLT2i group, 
currently available in Pakistan. These both are 
the recommended options for the management 
of T2DM either as a monotherapy or as add-on 
therapy with other antidiabetic agents12 with a 
reported improvement in HbA1c  up to 1.8%.13   The 
most common adverse effects reported with these 
novel agents are genital infections (GIs) and urinary 
tract infections (UTIs).
 There is limited published data on the efficacy 
and safety of both agents of this novel anti-diabetic 
group, empagliflozin and dapagliflozin, among 
the Pakistani population.14,15 Hence, we aimed 
this study to know about the efficacy of SGLT2i in 
terms of glycemic control and to report its effects 
on other metabolic parameters like reduction in the 
Body Mass Index (BMI) and change in the serum 
creatinine level along with adverse effects on 
Pakistani population in real-world practice.
METHODS
 This retrospective cohort study was conducted 
at the outpatient clinics of the Endocrine section of 
Aga Khan University Hospital Karachi (AKUH), 
Pakistan. The Endocrine clinics of our hospital 
cater more than 170 patients daily out of which 
more than 90% are having T2DM.
 We reviewed the outpatient records of all the 
T2DM patients who were prescribed with any agent 
of the SGLT2 inhibitors group (dapagliflozin or 
empagliflozin) from 1st July 2018 to 31st January 2019, 
due to failure to achieve adequate glycemic control 
on their existing antidiabetic agents. The protocol of 
this study was approved by the university’s ethical 
committee (ERC number 2019-1034-2727, dated 
February 19, 2019) and the study was carried out 
under the Helsinki ethics principles. To preserve the 
confidentiality of study participants, we coded each 
participant and removed their personal details.
 Data collection was started by reviewing 
the files at Health Information Management 
System (HIMS) of AKUH and was noted in the 
predefined study questionnaire by the primary 
author. We recorded the data regarding patients’ 
demographics including age, gender, antidiabetic 
agents they were taking before starting SGLT2i, 
baseline HbA1c, BMI, and serum creatinine level.
Inclusion and Exclusion criteria:  We included the 
patients who were of 18 years or older,of either 
gender with insufficient glycemic control (HbA1c > 
7%). We excluded all patients with T1DM, pregnant 
women, or those planning to conceive, history of 
recurrent UTI (with a frequency of at least three 
UTIs/year or two UTIs in the last six months), 
renal impairment, any malignancy, chronic liver 
disease, on any medicine like steroids, antibiotics, 
current or previous acute complications of diabetes 
like hyperglycemic hyperosmolar state, diabetic 
ketoacidosis (DKA), or any electrolyte imbalance. 
 The primary endpoint for our study was the 
change in the HbA1c at three and six months 
from baseline. Secondary endpoints were the 
possible changes in the BMI, daily insulin and or 
sulphonylureas (SU) dose, and serum creatinine 
from baseline at three and six months of follow up 
OPD visits. Safety was also assessed via reporting 
of adverse drug events (AEs) on the basis of history 
and lab evidence where appropriate. AEs of special 
interest, UTI, GTI, volume depletion/hypotension, 
diabetic ketoacidosis (DKA), electrolyte imbalance, 
gangrene, spontaneous fracture, or any other 
noted by the study participant.
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Statistical analysis: Mean±standard deviation 
(SD) was calculated for the continuous variables, 
percentages, and counts were calculated for the 
nominal variables. To determine the changes in 
baseline clinical characteristics according to the im-
provement in HbA1c, independent t-test was used 
for continuous variables and Pearson’s chi-square 
test was used for the categorical variables. We com-
pared HbA1c, BMI at baseline, and at three and six 
months using the paired t-test considering p-value 
of <0.001 as statistically significant at a confidence 
interval of 95%. All the statistical analysis was per-
formed on SPSS version 19.0 (IBM Co., USA).
RESULTS
 Among the Type-2 diabetic patients, initial 
100 patients who were prescribed with SGLT2 
inhibitors and who followed us on 3 and 6 months 
as an outpatient were included in this study. The 
mean age of the study participants was 52 years 
and the majority (56%) were females. The average 
duration of Diabetes was 12 years and the mean 
BMI was 32.4 ±5.9kg/m2. About half (49%) of the 
participants were insulin users and one-third (32%) 
were on SU. Table-I.
 After three months of SGLT2 intake, HbA1C 
levels substantially improved from a baseline value 
of 8.7 ± 1.5% to 7.9 ± 1.2% (P < 0.01). Likewise, BMI 
decreased from 32.4±5.9kg/m2.  kg/m2 at baseline 
to 31.8±5.8 kg/m2 (P < 0.01) at 3-months. After six 
months of SGLT2 treatment, HbA1C levels further 
decreased at 7.5 ± 1.1 in comparison to baseline 
measurements (P < 0.01). Similarly, the BMI of 
the patients improved from 32.4±5.9kg/m2.  kg/
m2 at baseline to 31.4±5.8kg/m2 at 6 months of 
treatment. The average insulin requirement has 
decreased from 93.5±55.8 IU at baseline to 85±49.3 
IU at three months and then 81.4±47.7 IU at six 
months (P < 0.01). Table-II and III.
DISCUSSION
 This single-center 6 months study from Pakistan 
shows SGLT2 inhibitors are effective in the Pakistani 
population not only in glycemic control but also in 
SGLT2I in patients with Type-2 Diabetes
Table-I: Baseline clinical characteristics
of the study participants.
Age (years) 51.9 ±10.4
Gender n (%)
   Male 44 (44)
   Female 56 (56)
   BMI, kg/m2 32.4 ± 5.9
   Creatinine 0.8 ± 0.1
Current treatment
   Insulin takers (BB + premix) 49 (49%)
   SU 32 (32%)
   SU + Basal Insulin 9 (9%)
   Others 10 (10%)
BB: Basal Bolus, SU: Sulphonylureas.
Table-II: Endpoints with changes at three and six months.
Variable Baseline 3 months 6 months p-value *
HbA1C 8.7 ± 1.5 7.9 ± 1.2 7.5 ± 1.1 < 0.01
BMI, kg/m2 32.4 ± 5.9 31.8 ± 5.8 31.4 ± 5.8 < 0.01
Creatinine 0.79 ± 0.1 0.75 ± 0.1 0.71 ± 0.1 < 0.01
Medications 
SU
Glimepiride (mg/day) 5.1 ± 2.4 4.2 ± 2.8 3.9 ± 2.9 0.01
Gliclizides (mg/day) 75 ± 37.9 58 ± 11.1 52.5 ± 43.1 0.01
Insulin (units /day)
Insulin 93.5 ± 55.8 85 ± 49.3 81.4 ± 47.7 < 0.01
Baseline was taken as Reference.







Nausea and UTI 1%
Abdominal pain and UTI 1%
Polyuria 1%
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the weight reduction and other metabolic effects 
with fewer side effects. Our study results further 
strengthens the outcome data from the previous 
studies,7,8,16 mostly done in the developed countries, 
by showing significant improvement in different 
metabolic parameters in the diverse population 
with T2DM in the real-world setting in Pakistan.
 Reduction in the HbA1c observed in this study, 
from 8.7 ± 1.5% to 7.9 ± 1.2% at 3 months and further 
reduction to 7.5 ± 1.1 at 6 months is comparable 
to the results of other real world studies and trials 
in which agents of this group were either used 
in combination or as monotherapy and showed 
improvement in HbA1c up to 1.8%.13-18 This 
reduction in HbA1c and improvement in insulin 
sensitivity and decrease in insulin resistance 
along with a reduction in the beta-cell loss as 
reported by Merocvi A, et al.19 make SGLT2i as 
a potent agent to be used in combination or as 
monotherapy as supported by  EASD- ADA 
position statement for DM management.20
 Most patients with T2DM are obese or overweight 
and weight loss in a diabetic patient is among the 
desired outcome because of its impact on insulin 
sensitivity, overall glycemic control, and long-term 
morbidities.21 A decrease in the BMI noted in our 
study is also comparable to other studies.16,18 We 
found a decrease in BMI from 32.4 ±5.9 kg/m2 
to 31.8±5.8 kg/m2 and 31.4±5.8 kg/m2 at 3 and 6 
months respectively. Weight reduction associated 
with SGLT2i likely observed is mainly because of 
their glycosuria induced energy loss and reduction 
in the fat mass was found to be sustained for more 
than two years of treatment as reported by Bolinder 
J et al.22 Because of this weight reduction and 
improvement in BMI one can expect a decrease in 
daily dose requirement of insulin and SU as seen 
in this study and other clinical studies on this drug 
group.16, 18, 23 This decrease in insulin and SU further 
decreases the chances of weight gain and the risk of 
hypoglycemia associated with both of these agents.
 We observed a decrease in serum creatinine from 
0.79±0.1 mg/dl to 0.71±0.1mg/dl and 0.75±0.1mg/
dl at 3 and 6 months. Evidence from different trials, 
meta-analysis, systemic reviews, and real-world 
studies has shown   the renoprotective effect of 
SGLT2Is, independent of their glycemic effects.24-26 
They have been associated with a reduction in the 
risk for major adverse renal outcomes among T2DM 
patients and have also shown a decrease in the 
progression of renal disease over a follow-up period 
of 3.1 years.9 CANVAS program also reported a 
reduction in the multiple renal outcomes up to 40%, 
including improvement in the estimated glomerular 
filtration rate, eGFR and in the progression of 
proteinuria, need for renal replacement therapy, or 
mortality from renal causes.24 
 Treatment with SGLT2i in our study was 
reasonably well tolerated; most common AEs 
reported were urinary tract infections (7%) and 
genital tract infections (3%), no events were severe, 
were treated effectively along with discontinuation 
of the drug. Incidence of UTIs reported in the 
published clinical trials is also in a similar range, 
from 4% to 9 % and the raw event rate of GTIs has 
been reported around 4.7% in one recent meta-
analysis by Liu et al.27 Given that SGLT2i are 
reported to be associated with an enhanced risk of 
UTI and GTI, further long term follow up studies 
are warranted to confirm these findings. 
Strengths & Limitations of the study: This is 
among the first few real-world studies on the 
efficacy and safety of SGLT2i from Pakistan with 
promising results, showing this group of the 
agent can be prescribed with confidence in our 
population. Being a retrospective study, it has 
some limitations in the collection of data, and, also 
being a single-center study with a small sample 
size, therefore, is not a true representation of the 
whole Pakistani population.
CONCLUSION
 Use of SGLT2i as add on therapy is effective in 
the Pakistani population not only in improving 
glycemic control but also leading to weight 
reduction and with a decrease in daily doses of 
sulphonylurea and insulin with a very low number 
of observed adverse events.
Recommendation: Further prospective studies are 
needed in this part of the world to report their 
effects on cardiovascular, renal, and other chronic 
complications of diabetes.
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